INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
NewYork–Presbyterian Hospital
Nueva York, Estados UnidosPublicaciones en colaboración con investigadores/as de NewYork–Presbyterian Hospital (16)
2021
-
Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 2, pp. 97-105
-
Small-molecule inhibitors targeting Polycomb repressive complex 1 RING domain
Nature Chemical Biology, Vol. 17, Núm. 7, pp. 784-793
-
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification—an approach to classification of patients with t-MDS
Leukemia, Vol. 35, Núm. 3, pp. 835-849
2020
-
Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study
Leukemia, Vol. 34, Núm. 8, pp. 2125-2137
2016
-
Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma
Blood, Vol. 128, Núm. 9, pp. 1174-1180
2015
-
Multicenter Study of Epidemiological Cutoff Values and Detection of Resistance in Candida spp. to Anidulafungin, Caspofungin, and Micafungin Using the Sensititre YeastOne Colorimetric Method
Antimicrobial Agents and Chemotherapy, Vol. 59, Núm. 11, pp. 6725-6732
2014
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposal for an evidence-based stage classification system for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S65-S72
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the N and M components for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S81-S87
-
The IASLC/ITMIG thymic epithelial tumors staging project: Proposals for the T component for the forthcoming (8th) edition of the TNM classification of malignant tumors
Journal of Thoracic Oncology, Vol. 9, Núm. 9, pp. S73-S80
2010
-
Monoclonal gammopathy of undetermined significance: A consensus statement: Guideline
British Journal of Haematology, Vol. 150, Núm. 1, pp. 28-38
2009
-
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: Impact of a dose-modification guideline
British Journal of Haematology, Vol. 144, Núm. 6, pp. 895-903
2008
-
Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: Results from the APEX study
British Journal of Haematology, Vol. 143, Núm. 4, pp. 511-519
-
Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma
British Journal of Haematology, Vol. 143, Núm. 2, pp. 222-229
2007
-
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial
Blood, Vol. 110, Núm. 10, pp. 3557-3560
-
Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma
British Journal of Haematology, Vol. 137, Núm. 5, pp. 429-435
2005
-
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 352, Núm. 24, pp. 2487-2498